Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltnane, Monica V. Estrada, Violeta Sanchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. DoimiHenry Gomez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, Justin M. Balko

Research output: Contribution to journal › Comment/debate › peer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)'. Together they form a unique fingerprint.

Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors(Clin Cancer Res. (2016)22:6 (1499-509) DOI: 10.1158/1078-0432.CCR-15-1125)

Fingerprint

Medicine & Life Sciences